You are here

Article Text

Article menu
Download PDFPDF
Original research
Expression and clinical significance of a new neuroendocrine marker secretagogin in cervical neuroendocrine carcinoma
  1. Li Yu1,2,
  2. Suye Suye1,
  3. Rui Huang1,
  4. Qinchun Liang3,
  5. Chun Fu1
  1. 1 Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
  2. 2 Department of Gynecology, Yiyang Central Hospital, Yiyang, Hunan, China
  3. 3 Department of Pathology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
  1. Correspondence to Professor Chun Fu, Department of Obstetrics and Gynecology, Second Xiangya Hospital, Changsha 410011, China; fuchun0814{at}csu.edu.cn

Abstract

Aims To explore the expression of secretagogin (SCGN) in neuroendocrine carcinoma of the uterine cervix and analyse its relationship with clinicopathological characteristics and prognosis.

Methods From January 2010 to December 2017, 44 patients with cervical neuroendocrine carcinoma undergoing surgery were included in the study group, and 55 patients with cervical non-neuroendocrine carcinoma (including 30 cases of cervical squamous cell carcinoma and 25 cases of cervical adenocarcinoma) undergoing surgery were included in the control group. Immunohistochemical staining of SCGN was performed in both groups and compared with three common neuroendocrine markers, chromogranin A, synaptophysin (Syn) and CD56 in the study group. Detailed clinicopathological data of the two groups were analysed, and the patient survival in the study group was followed up.

Results The positive expression of SCGN in cervical neuroendocrine carcinoma, cervical adenocarcinoma and squamous cell carcinoma was 65.9% (29/44), 8% (2/25) and 0%, respectively. The positive expression of SCGN in cervical neuroendocrine carcinoma was significantly higher than that in cervical adenocarcinoma and squamous cell carcinoma (χ2=44.5, p<0.001). There were no statistical differences among the positive expression of SCGN and three common neuroendocrine markers (p>0.05 for all). The intensity of SCGN staining in patients with cervical neuroendocrine carcinoma with lymph node metastasis was significantly higher than that in patients without lymph node metastasis (p=0.020). However, there was no significant association between SCGN expression and survival among patients with cervical neuroendocrine carcinoma (p=0.633).

Conclusions SCGN is a new neuroendocrine marker for cervical neuroendocrine carcinoma, whose expression correlates with lymph node metastasis.

  • neuroendocrine tumors
  • cervix uteri
  • diagnosis

Data availability statement

Data are available upon reasonable request.

https://doi.org/10.1136/jclinpath-2020-206889

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Data availability statement

    Data are available upon reasonable request.

    View Full Text

    Footnotes

    • Handling editor Mona El-Bahrawy.

    • LY and SS contributed equally.

    • Contributors All authors met criteria for scientific contribution for this work.

    • Funding This study was supported by the National Natural Science Foundation of China (81771546), Hunan Provincial Department of Finance and Education Project (2018) number 33: (2050205-30299-50502) and Hunan Provincial Science and Technology Department (2018SK52508).

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.